160162-42-5

中文名称 SR 11302

英文名称 SR 11302

CAS 160162-42-5

分子式 C26H32O2

分子量 376.53

MOL 文件 160162-42-5.mol

更新日期 2024/07/24 18:26:20

160162-42-5 结构式

基本信息物理化学性质图谱信息 SR 11302价格(试剂级) 常见问题列表

基本信息

中文别名

化合物SR 11302

英文别名

SR 11302
RQANARBNMTXCDM-DKOHIBGUSA-N
(E,E,Z,E)-3-Methyl-7-(4-methylphenyl)-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoicacid
2,4,6,8-Nonatetraenoic acid, 3-methyl-7-(4-methylphenyl)-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (2E,4E,6Z,8E)-

物理化学性质

沸点541.6±30.0 °C(Predicted)

密度1.048±0.06 g/cm3(Predicted)

储存条件-20°C储存

溶解度溶于二甲基亚砜

酸度系数(pKa)4.67±0.33(Predicted)

形态结晶固体

颜色Light yellow to yellow

图谱信息

SR 11302(160162-42-5)核磁图(¹HNMR)

SR 11302价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2025/05/22	HY-15870	SR 11302	160162-42-5	1 mg	990元
2025/05/22	HY-15870	SR 11302 SR 11302	160162-42-5	5mg	1800元
2025/05/22	HY-15870	SR 11302 SR 11302	160162-42-5	10mM * 1mLin DMSO	1980元

常见问题列表

生物活性

SR 11302 是激活蛋白-1 (AP-1) 转录因子抑制剂。SR 11302 是一种类视黄醇，可特异性抑制 AP-1 活性，而不会激活视黄酸反应元件 (RARE) 的转录。

靶点

AP-1

体外研究

SR 11302 (SR11302) show strong anti-AP-1 activity with selective binding with RARα and RARγ, but not with RARβ and RXRα.
SR 11302 (SR-11302; 1 μM) inhibits AP-1 transcription factor activity and decreases aldosterone levels by 61.9% in hypoxia-treated cells.
SR 11302 (SR-11302; 2 µM; 48 hours) inhibits Helicobacter pylori ( H. pylori )-induced cell proliferation in adenocarcinoma gastric (AGS) cells.
SR 11302 (2 µM; 24 hours) inhibits H. pylori -induced expression of β-catenin and c-myc in AGS cells.

体内研究

SR 11302 (SR11302; low dose 0.5 mg/kg and high dose 1 mg/kg body weight; orally gavaged daily) treatment reduces the total vascular lesion number and lesion size in Vldlr ^-/- mice in a dose-dependent manner.

Animal Model:	Vldlr ^-/- mice
Dosage:	Low dose 0.5 mg/kg and high dose 1 mg/kg body weight
Administration:	Orally gavaged daily from P5 to P15
Result:	High-dose from P5 to P15 reduced the total vascular lesion number by 48% and decreased the lesion size by 40%, without detectable signs of toxicity in mice, including no change in body weight.